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Abstract: Testosterone compounds have been available for almost 70 years, but the 
pharmaceutical formulations have been less than ideal. Traditionally, injectable testosterone 
esters have been used for treatment, but they generate supranormal testosterone levels shortly 
after the 2- to 3-weekly injection interval and then testosterone levels decline very rapidly, 
becoming subnormal in the days before the next injection. The rapid ﬂ  uctuations in plasma 
testosterone are subjectively experienced as disagreeable. Testosterone undecanoate is a new 
injectable testosterone preparation with a considerably better pharmacokinetic proﬁ  le. After 2 
initial injections with a 6-week interval, the following intervals between two injections are almost 
always 12-weeks, amounting eventually to a total of 4 injections per year. Plasma testosterone 
levels with this preparation are nearly always in the range of normal men, so are its metabolic 
products estradiol and dihydrotestosterone. The “roller coaster” effects of traditional parenteral 
testosterone injections are not apparent. It reverses the effects of hypogonadism on bone and 
muscle and metabolic parameters and on sexual functions. Its safety proﬁ  le is excellent due to 
the continuous normalcy of plasma testosterone levels. No polycythemia has been observed, and 
no adverse effects on lipid proﬁ  les. Prostate safety parameters are well within reference limits. 
There was no impairment of uroﬂ  ow. Testosterone undecanoate is a valuable contribution to 
the treatment options of androgen deﬁ  ciency.
Keywords: testosterone treatment, testosterone undecanoate, pharmacokinetic proﬁ  le, clinical 
efﬁ  cacy, side effects, sexual dysfunction
Introduction to the various testosterone 
preparations for treatment of hypogonadal men
Soon after its chemical identiﬁ  cation more than 70 years ago, the male hormone 
testosterone (T) became pharmaceutically available. But it took  considerable time 
before convenient and safe preparations were developed. Three approaches have been 
used to make T therapeutically effective: (1) routes of administration, (2) esteriﬁ  cation 
in the 17β-position, and (3) chemical modiﬁ  cation of the molecule, or a combination 
of approaches. In clinical practice, particularly in the perception of the patient, the 
route of administration is most relevant, and is used to categorize the preparations 
described here. Recent reviews of treatment modalities may be recommended (Gooren 
and Bunck 2004; Nieschlag 2006).
Free unesteriﬁ  ed T is absorbed well from the gut but is effectively metabolized and 
inactivated in the liver before it reaches the target organs. Pharmacological changes 
of the T molecule in the 17α-position render the molecule orally effective. Alkylated 
derivatives of T including methyltestosterone and ﬂ  uoxymesterone are administered 
orally or sublingually. They are metabolized by the liver, like natural T, but more slowly, 
and, like T, interact directly with androgen receptors. Clinical responses are variable 
and plasma levels cannot be determined accurately, because alkylated androgens are not 
recognized by most T assays. Prolonged use (especially the 17α – alkylated androgens) Clinical Interventions in Aging 2007:2(4) 578
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has been associated with hepatotoxicity including hepatocellu-
lar adenoma, cholestatic jaundice, and hemorrhagic liver cysts 
(Gooren and Bunck 2004; Bagatell and Bremner 1995).
Oral testosterone undecanoate
Testosterone undecanoate (TU) is T esteriﬁ  ed in the 17β-
position with a long aliphatic sidechain, undecanoic acid, 
dissolved in oil and encapsulated in soft gelatin. Of the 40 
mg capsules, 63% (25 mg) is T. After ingestion, for a portion 
(around 5%) of the administered dose the route of absorption 
from the gastrointestinal tract is shifted from the portal vein 
to the thoracic duct. Due to its aliphatic chain it travels with 
lipids in the lymph and reaches the general circulation via 
the subclavian vein, thus avoiding a ﬁ  rst pass through the 
liver and subsequent metabolism of T (Behre et al 2004). 
The dosing is as a rule 80 mg twice daily.
For its adequate absorption from the gastrointestinal tract 
it is essential that oral TU is taken with a meal that contains 
dietary fat. Maximum serum levels are reached 2–6 hours 
after ingestion, and result in ﬂ  uctuating serum T levels (for 
a review see Behre et al 2004). To increase shelf-life the 
preparation was recently reformulated and the oil in the cap-
sule is now castor oil. Recent studies show that there is dose 
proportionality between serum T levels and the dose range 
of 20–80 mg. With a dose of 120–240 mg per day, over 80% 
of hypogonadal men showed plasma T levels in the normal 
range over 24 hours (Bagchus et al 2003).
Transbuccal T administration
Transbuccal administration of T provides a means of oral 
administration of T. It is marketed as a biopellet to be pressed 
on the gum above the incisor tooth; then the buccal ﬁ  lm that 
develops is be put between the lower gum and cheek. The 
resorption of T through the oral mucosa avoids intestinal 
absorption and subsequent hepatic inactivation of T. An in-
formative study is the report of Dobs et al (2004). This study 
compared treatment with T buccal system (Striant®, Colum-
bia Laboratories, Inc.) 30 mg twice daily, with a transdermal 
gel delivery system, 5 g containing 1% (50 mg) T, daily for 
14 days in androgen-deﬁ  cient men. 92.3% of T buccal system 
and 83.3% of T gel patients had C(ave[0–24]) within the 
normal range of 10.4–36.4 nmol/L (3.0–10.5 ng/mL). Mean 
total T values were not different in the T buccal system group 
(C[ave(0–24)] 16.7 ± 4.7 nmol/L; 4.8 ± 1.4 ng/mL) compared 
with the T gel group (C[ave(0–24)] 15.9 ± 4.8 nmol/L; 4.6 
± 1.4 ng/mL). The effects of buccal T on sexual function-
ing were comparable with those of parenteral T enanthate 
(Wang et al 2004b).
Sublingual T administration
Sublingual application of T has been tested with the inclusion 
of the hydrophobic T molecule with 2-hydroxypropyl-
β-cyclodextrin (HPBCD). HPBCD enhances T solubility and 
absorption but HPBCD itself is not absorbed (Stuenkel et al 
1991). The integrated dihydrostestosterone (DHT)/T ratio 
was normal. Serum E2 remained in the normal range. There 
were no accumulations of steroid hormones over the 7 day 
test period (Stuenkel et al 1991; Wang et al 1996). Effects 
on sexual behavior were comparable to those of parenteral 
administration of 200 mg T enanthate every 20 days.
Transdermal delivery
Testosterone can be delivered to the circulation through the 
intact skin, both genital and non-genital (Gooren and Bunck 
2004; Nieschlag 2006). Transdermal administration delivers 
T at a controlled rate into the systemic circulation avoiding 
hepatic ﬁ  rst pass and reproducing the diurnal rhythm of T 
secretion, without the peak and through levels observed in 
long-acting T injections.
Scrotal T patch
Scrotal patches were ﬁ  rst designed to deliver T through the 
scrotal skin, where the permeability is 5 times greater than 
for other skin sites (Behre et al 2004). Clinical results were 
satisfactory. Transdermal scrotal T administration is associ-
ated with high levels of DHT as a result of high concentra-
tions of 5α-reductase in the scrotal skin (Behre et al 2004). 
The patch may be irritating and the use is not feasible if the 
scrotal surface is not adequate. The scrotal patches sometimes 
fell off the scrotum, leaving the patient undersubstituted. To 
overcome these limitations, non-scrotal skin patches have 
been developed.
Non-scrotal T patch
These patches have a reservoir containing T with a 
permeation-enhancing vehicle and gelling agents (Meikle 
et al 1996). Clinical efﬁ  cacy was as good as with conventional 
T ester injections. Though pharmacokinetically and clini-
cally satisfactory, there are adverse effects such as local skin 
reactions. Fifty percent of men participating in a clinical trial 
reported transient, mild to moderate erythema at sometime 
during therapy (Meikle et al 1996).
Testosterone gel
Testosterone gel is also used for replacement therapy. 
Testosterone gel is hydro-alcoholic, 1% (10 mg T/g of 
gel), and administered at between 5 and 10 g of gel a Clinical Interventions in Aging 2007:2(4) 579
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day, amounting to 50 and 100 mg T, respectively. The 
pharmacokinetics of T gel have been extensively studied 
(Meikle et al 2004). Serum T levels rose 2- to 3-fold 2 hours 
after application and rose further to 4- to 5-fold after 24 hours. 
Thereafter serum T remained steady in the upper range of 
normal and returned to baseline within 4 days after termina-
tion of application of T gel (Meikle et al 2004). Mean DHT 
levels followed the same pattern as T and were at or above the 
normal adult male range. Serum E2 levels rose and followed 
the same patterns as T. Later studies showed that 9%–14% 
of the T administered is bioavailable. Steady state T levels 
are achieved 48–72 hours after the ﬁ  rst application (Wang 
et al 2000). The formulation of the T gel allows easy dose 
adjustments (50–75–100 mg T gel) (Wang et al 2004a).
The clinical efﬁ  cacy of transdermal T gel on various andro-
gen-dependent target organ systems has been well documented. 
The safety proﬁ  le showed that prostate-speciﬁ  c antigen levels 
rose in proportion to the increase of T levels but did not exceed 
normal values. Skin irritation was noted in 5.5% of patients 
in the study (Wang et al 2004a). Transfer from one person to 
another was found to be insigniﬁ  cant (Rolf et al 2002). No 
increase of serum T was found after intense rubbing of skin with 
persons whose endogenous T levels had been suppressed (Rolf 
et al 2002). But recently, three cases of transfer from fathers to 
their children have been reported (Brachet et al 2005).
Intramuscular administration
Testosterone implants
Subdermal pellet implantation was among the earliest 
effective treatment modalities for clinical use of T and 
became an established form of androgen replacement by 
1940 (for review (Kelleher et al 2004)). Several reports 
have outlined its desirable pharmacological properties but 
its use and merits and its complications (such as infection 
and extrusion) have been best documented by the group of 
Handelsman (Kelleher et al 2004).
Testosterone esters
The most commonly used forms of androgen replacement 
therapy include 17β-hydroxyl esters of T administered with 
slow-release, oil-based vehicles. Commonly used intramuscular-
injectable T esters are T enanthate and cypionate (Behre et al 
2004; Gooren and Bunck 2004; Nieschlag 2006).
Testosterone enanthate is one of the most widely used 
intramuscular T esters. At a dose of 200–250 mg the optimal 
injection interval is 2–3-weeks but peak and through values 
are clearly above and below the normal range (Behre et al 
2004).
Testosterone propionate has a terminal half-life of only 
19 hours. After a single injection of 50 mg the maximum 
concentration is reached after approximately 14 hours (Behre 
et al 2004). On the basis of this proﬁ  le, injection intervals 
are only 2–3 days with peak and through values above 
and below the normal range and therefore not suitable for 
monotherapy of T deﬁ  ciency. Alternatively, 100 mg weekly 
may be given.
Other T esters are T cypionate and T cyclohexanocarbox-
ylate. The pharmacokinetics of these T esters are very simlar 
to those of T enanthate (Behre et al 2004). Administration 
of 200 mg every 2-weeks provides an acceptable form of T 
replacement.
Several commercially available T preparations contain 
a number of short- and longer-acting T esters aiming to 
deliver more even serum T levels. Pharmacokinetic studies 
of these preparations show that this goal is not achieved. The 
peak values are higher than in single T ester preparations 
and resulting plasma T levels show even larger ﬂ  uctuations 
(Behre et al 2004). So, most intramuscular presentations of 
T are not ideal. With the most commonly used T esters a 
maximum concentration follows approximately 72 hours 
after injection. T levels slowly diminish during the follow-
ing 10–14 days showing an exponential decline of serum T 
levels, reaching baseline at approximately day 21 (Behre 
et al 2004). As a result the T levels before the next injection 
are low (Behre et al 2004; Gooren and Bunck 2004). The nor-
mal pattern of circadian rhythm of T is not provided, though 
it is questionable whether the circadian rhythm has much 
therapeutic relevance. The injections are painful (Gooren 
and Bunck 2004). Although levels of 5α dihydrotestosterone 
are normal, androgen metabolites are frequently not physi-
ological and estradiol concentrations may become excessive 
in some men. The proﬁ  le of T levels may be accompanied 
by disturbing ﬂ  uctuations in sexual function, energy level, 
and mood (Gooren and Bunck 2004; Nieschlag 2006). High 
post-injection levels of T predispose the patient to acne and 
polycythemia, and elevated estradiol predisposes to gyneco-
mastia. In some patients, injections may be associated with 
bleeding or bruising (Nieschlag 2006). However, these long-
acting testosterone preparations have long been the mainstay 
of T treatment and they are the most cost-effective methods, 
with administration of 200 to 400 mg every 2–4-weeks. The 
200 mg injection will maintain normal T for approximately 
2-weeks while 300 mg doses are required for eugonadal 
ranges for approximately 3-weeks (Behre et al 2004).
Androgen replacement with 5α reduced testosterone: 5α 
dihydrotestosterone.Clinical Interventions in Aging 2007:2(4) 580
Yassin and Haffejee
The effects of T are mediated directly as testosterone 
or after conversion to either 5α DHT or estradiol locally in 
target tissues. The reduction of T to DHT is an ampliﬁ  cation 
mechanism of the androgenizing effects of T. DHT binds to 
the same receptor as T but its receptor binding is stronger, 
resulting in a considerable higher biopotency than T itself. 
DHT, as opposed to T, cannot be aromatized to estradiol 
and acts, therefore, as a pure androgen. In certain clinical 
conditions a pure androgen might have advantages over 
aromatizable testosterone, such as cases of a microphallus, 
hypogonadal men with a susceptibility to gynecomastia or 
constitutionally delayed puberty in boys. Oestrogens are 
pivotal in closure of the epiphyses in puberty, and a non-
aromatizable androgen might allow some extra gain in height 
by slowing the closure of the pubertal epiphyses. Oestrogen 
effects on the prostate might be deleterious (Carruba 2006) 
and in this regard DHT might be the preferred androgen for 
the androgen-deﬁ  cient aging male. Studies of DHT admin-
istration to hypogonadal men show that DHT maintains sex 
characteristics, increases muscle mass and improves sexual 
functions without signiﬁ  cant increases in prostate size (Ly 
et al 2001; Wang and Swerdloff 2002).
Review of pharmacology, mode 
of action, pharmacokinetics of 
testosterone depot injection
In search of a better intramuscular long-acting testoster-
one preparation for male contraception, the world health 
organization (WHO) Special Programme of Research, 
Development and Research Training in Human Reproduc-
tion initiated search activities for identiﬁ  cation of suitable 
fatty acid side chains for esteriﬁ  cation of T (Crabbe et al 
1980). It appeared that T esteriﬁ  ed with TU showed more 
favorable long-term kinetics (Herz et al 1985; Behre et al 
2004). The ﬁ  rst TU preparation was developed in China 
(Gu et al 2003; Zhang et al 2006). Unfortunately, the injec-
tion volume of 8 mL for 1000 mg TU caused problems at 
the injection site. Subsequently, by use of a special galenic 
formulation based on benzyl benzoate and reﬁ  ned castor 
oil, Jenapharm/Schering were able to develop a suitable 
intramuscular TU preparation with a volume of 4 mL con-
taining 1000 mg TU. Intramuscular TU is currently not ap-
proved for use in the US, but is prescribed in Europe, Latin 
America, and Asia under the tradename Nebido® (Bayer 
Schering Pharma AG, Berlin, Germany), and in Australia 
and Spain under the tradename Reandron 1000® (Bayer 
Schering Pharma AG, Berlin, Germany) for the treatment 
of male hypogonadism.
Toxicology and pharmacology
The active pharmacological principle of TU is testosterone 
itself. After entering the peripheral circulation, TU (molecular 
weight 456.7 Da) is hydrolyzed to T which may then exert 
its androgenic activity(Horst et al 1976). Therefore, in prin-
ciple, the toxicology of TU is the same as for other cleavable 
T fatty acid esters such as T propionate (3 carbon atoms), 
T enanthate (7 carbon atoms), or T cypionate (8 carbon atoms). 
In contrast to these fatty acid esters the kinetics for side chain 
cleavage of the saturated aliphatic fatty acid undecanoic acid 
with 11 carbon atoms turned out to be considerably longer, 
permitting much longer injection intervals, at the same time 
as preventing supra- or sub-physiological serum T levels.
TU had been available as an oral preparation for more 
than 30 years. It is well-tolerated, but the bioavailability of T 
leaves much to be desired. It requires careful dosing at least 
two times a day and it must be taken with fatty meals in order 
to achieve acceptable plasma T levels (Bagchus et al 2003).
Pharmacokinetics of injectable depot TU: The relationships 
between intramuscular TU dose ( 31, 62.5, 125, 250, and 500 
mg/kg body weight s.c.) and T serum levels were investigated 
in male rats (Callies et al 2003). A single injection of 125 mg 
TU/kg body weight is effective in inducing physiological T 
levels in orchiectomized rats for a minimum of 4-weeks. High 
dose TU ( 500 mg/kg body weight) given as a single injection 
results in supraphysiological T serum concentrations for up 
to 6-weeks in non-orchiectomized animals. TU was superior 
to other preparations releasing T (T pellets s.c. T ﬁ  lled s.c. 
Silastic® [Dow Corning Corp.] implants, s.c. testosterone 
propionate) in inducing physiological T lelvels.
Partsch et al (1995) compared T serum levels after single in-
tramuscular injections of 10 mg TU or T enanthate (TE)/kg body 
weight in 5 long-term orchidectomized cynomolgus monkeys 
(Macaca fascicularis). For pharmacokinetic characteristics such 
AUC (4051 vs 1771 nmol x h/L), residence time (41 vs 12 days), 
terminal half-life (26 vs 10 days), maximal T concentration (73 
vs 177 nmol/L), and time at maximal T concentration (11 vs 
1 days), TU showed pharmacokinetic and pharmacodynamic 
properties clearly superior to those of TE. Animals treated with 
TU also showed a signiﬁ  cantly longer ejaculatory response 
(14-weeks ) than those treated with TE (7-weeks).
Pharmacokinetics in men
The first detailed pharmacokinetic investigation of the 
injectable TU preparation manufactured in China (Zhang 
et al 1998), administering 2 single doses in hypogonadal 
men. Eight patients with Klinefelter’s syndrome received 
either 500 mg or 1000 mg of TU by intramuscular injection; Clinical Interventions in Aging 2007:2(4) 581
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3 months later, the other dose was given to each of the 
participants. Every week or every second week after the injec-
tions, the serum total T concentrations were measured. The 
whole observation period was only 8 or 9-weeks. The single-
dose injections maintained serum T levels within the normal 
range for at least 7-weeks without immediately apparent side 
effects. Of considerable interest was the observation that the 
pharmacokinetic proﬁ  les of T were different when 500 mg TU 
was given as the ﬁ  rst injection or as the second one. Somewhat 
unexpectedly, the peak T values obtained were lower when 
the 500 mg dose given as the second injection, compared with 
when the 500 mg dose was given ﬁ  rst. The authors speculate 
that long-term hypogonadism of these men may have induced 
faster cleavage or clearance mechanisms for TU and T by the 
time of the second injection. Another explanation proposed 
was that the residual endogenous T is suppressed by the ﬁ  rst 
injection (decrease of LH and FSH), and that after the second 
injection, only exogenous T was measured.
In a following study (Nieschlag et al 1999) 13 hypo-
gonadal men received 4 intramuscular injections of TU at 
6-week intervals. T serum levels were never found to lie 
below the lower limit of normal, and only brieﬂ  y after the 
3rd and 4th injection were T serum levels above the upper 
limit of normal (Figure 1) while values peak and trough 
levels increased over the 24-week observation period. Serum 
estradiol and DHT followed the same pattern, not exceeding 
the normal limits. In order to better establish (von Eckardstein 
and Nieschlag 2002) suitable injection intervals for TU, 7 
hypogonadal men received injections at gradually increasing 
intervals between the 5th and 10th injection (starting with 
6-weeks injection interval) and from then on every 12-weeks. 
Steady state kinetics were assessed after the 13th injection. 
Cmax was 32.0 ± 11.7 nmol/L and half-life was 70.2 ± 21.1 
days. The mean Cmax of 32 nmol/L seen during steady-state 
with TU administration was lower than that achieved by 
Testogel® (Bayer) 100 mg/day (37.5 nmol/L); however, it 
was higher than with Testogel® 50 mg/day (28.8 nmol/L) and 
Androderm® (Watson Pharmaceuticals, Inc.,) patch 5mg/day 
(26.5 nmol/L). Before the next injection, the serum levels 
for T and its metabolites DHT and estradiol were mostly 
within the normal (eugonadal) range and showed a tendency 
to decrease with increasing injection intervals. The study 
concluded that after initial loading doses at 0 and 6-weeks, 
injection intervals of 12-weeks establish eugonadal values of 
serum testosterone in almost all men. A later study (Yassin 
and Saad 2005) analyzing 58 hypogonadal men receiving TU 
treatment every 3 months did not report elevations of DHT 
levels exceeding the physiological threshold.
In an open label, randomized, prospective study (Schubert 
et al 2004), TU (1000 mg TU 3 times every 6-weeks, there-
after every 9-weeks) was compared with TE (250 mg every 
3-weeks) in 40 hypogonadal men. In contrast to the group 
treated with TE, trough T levels (measured immediately 
before the new injection) in patients receiving TU remained 
within the physiological (eugonadal) range. This study was 
extended as a follow-up study for approximately 2.5 years 
of treatment (Morales et al 2006). All the patients in this 
study phase received 1000 mg TU every 12-weeks (the 
patients who had earlier received TU)) or 2 x 1000 mg TU 
every 8-weeks followed by 1000 mg TU every 12-weeks 
(the patients who had earlier received TE ). This regimen 
resulted in stable mean serum trough levels of T (ranging 
from 14.9 ± 5.2 to 16.5 ± 8.0 nmol/L) and estradiol (rang-
ing from 98.5 ± 45.2 to 80.4 ± 14.4 pmol/L). For T therapy 
with TU the authors recommended an initial loading dose 
of 3 × 1000 mg TU every 6-weeks followed by 1000 mg TU 
every 12-weeks. On the basis of pharmacokinetic studies the 
conclusion was reached that patients receiving TE could be 
switched to TU without interruption in therapy, but with an 
additional loading dose of TU 2 × 1000 mg every 8-weeks 
after switching from the short-acting TE to TU (Schubert 
et al 2004; Nieschlag 2006).
Clinical long-term experience up to 120-weeks was 
published in 2004 (Schubert et al 2004). Twenty-six hypo-
gonadal patients received TU (1000 mg TU/4mL) in a ﬁ  rst 
stage of the study in weeks 0, 6, 16, 26, and 36, followed by 
an additional stage of up to 120-weeks with injections every 
12-weeks. The supranormal peak concentrations of total 
and free T occurred 2-weeks after the ﬁ  rst injection, then a 
decrease to within the physiological range was observed. At 
the end of the study, during washout period, serum T levels 
declined to the low pre-treatment levels 14-weeks after the 
ﬁ  nal injection. A parallel increase of 17β-estradiol levels 
was seen, but there was an earlier decrease to pre-treatment 
levels by 4-weeks after the last injection. Serum LH and 
FSH were suppressed during the treatment period, while 
sex hormone binding globulin (SHBG) remained stable. The 
latter is probably an expression of the physiological range 
of achieved plasma testosterone levels; administration of 
high dose testosterone leads to a fall in plasma SHBG levels 
(Anderson et al 1996).
Serum prostate speciﬁ  c antigen (PSA) rose from 0.660 to 
0.976 ng/mL (p < 0.01) after 120-weeks, but did not exceed 
the normal range. Prostate volume increased from 19.6 to 26 
mL (p < 0.05). Osteocalcin rose from 0.734 to 1.049 nmol/L 
(p < 0.01). Bone mineral density (BMD) did not change. Clinical Interventions in Aging 2007:2(4) 582
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Standard laboratory tests and uroﬂ  ow did not change. Sexual 
interest (assessed by use of the AMS questionnaire) increased 
(reviewed in Harle et al 2005).
There is now long-term experience of up to more than 
8 years with TU in 22 hypogonadal men (Zitzmann 2006). 
Individual dosing intervals ranged from 10 to 14-weeks. Se-
rum trough levels of T were generally within the low-normal 
range, indicating sufﬁ  cient substitution. In contrast to short-
acting T esters, sensations of ﬂ  uctuations in androgen serum 
concentrations were rarely observed. When they were, they 
occurred during the last 2-weeks before the next injection, 
indicating loss of androgenic psychotropic effects. Summa-
rizing two key studies (von Eckardstein and Nieschlag 2002; 
Schubert et al 2004) the following administration regimen is 
recommended for TU therapy in hypogonadal men: After the 
ﬁ  rst injection of 1000 mg TU, the second injection of 1000 
mg TU is to be administered 6-weeks after the ﬁ  rst injection 
(loading dose) followed by injections every 12-weeks. While 
this schedule will generally be adequate, an individualization 
of TU therapy may be desirable (Zitzmann 2006). If the T 
serum concentration before the 4th injection lies between 10 
and 15 nmol/L then the injection interval should be every 
12-weeks. Should the T serum concentration at this time be 
lower than 10 nmol/L, then the injection interval is shortened 
to every 10-weeks. If the T level is greater than15 nmol/L, 
then the injection interval should be extended to every 14-
weeks. Additionally, clinical symptoms should be considered 
for individualization of injection intervals with TU therapy. 
The loading dose of TU achieved by the ﬁ  rst two injections 
with an interval of 8-weeks is also recommended for patients 
who are being transferred from short-acting T injections (eg, 
testosterone enanthate 250 mg) to treatment with TU.
Efﬁ  cacy studies, including any 
comparative studies
The efﬁ  cacy of TU has been compared with the previous 
gold standard of 250 mg TE i.m. every 3-weeks in a 30-
week controlled, prospective, randomized, parallel-group 
study (Schubert et al 2004). During the ﬁ  rst 30-weeks of 
the comparative phase, 40 hypogonadal men with T levels 
below 5 nmol/L were randomly assigned to either 250 mg 
TE i.m. every 3-weeks (n = 20) or TU 3 times at 6-week 
intervals followed by a 9-week interval. Following the ﬁ  rst 
30-weeks of the comparative part of the study, all patients 
Figure 1 Trough levels of testosterone after repeated injections of testosterone enanthate and testosterone undecanoate in 40 hypogonadal men (mean age 41, range: 
18–74 years).
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received TU every 12-weeks in the one-arm follow-up study 
over additional 30 months. In the ﬁ  rst 30-weeks there were 
no differences in sexual parameters (spontaneous morning 
erections, total erections, ejaculations) between the two 
groups. After 30-weeks, serum PSA levels in both treat-
ment groups had risen slightly, but remained stable during 
long-term TU administration and stayed within the normal 
range over the entire observation period. Prostate volume 
increased during the ﬁ  rst 30-weeks to a similar degree with 
both T preparations but then remained stable until the end 
of the follow-up study (Morales et al 2006). Comparing the 
mean baseline levels with the mean levels after follow-up, 
there was an increase of serum T (from 3.9 to 16.2 nmol/L), of 
PSA serum levels (from 0.27 to 0.75 ng/mL) and of prostate 
volume (from 14.5 to 20.2 mL), whereas a decline in serum 
total cholesterol (from 235.3 to 202.4 mg/dL), LDL choles-
terol (from 158.8 to 134.9 mg/dL), HDL cholesterol (from 
46.1 to 42.8 mg/dL), and triglycerides (from 199.9 to 161.2 
mg/dL) was observed. The decline in plasma HDL must be 
balanced against the improvement in the other classes of 
lipids. In the follow-up of these patients, in those receiving 
TU, plasma HDL returned to pre-treatment levels and then 
increased signiﬁ  cantly (Minnemann et al 2007).
Using a standardized self-evaluation questionnaire for as-
sessing psychosexual effects of TU treatment, it was found that 
scores for sexual thoughts/fantasies and sexual interest/desire 
doubled. Also the score for satisfaction of sex life increased. 
Improvements were seen for waking erections, total number 
of erections, and of ejaculations (Figure2). The psychologi-
cal parameters for depression, fatigue, and anxiety decreased 
within the ﬁ  rst 3–6-weeks and remained stable. There were 
no statistically signiﬁ  cant differences between TE and TU. 
No signiﬁ  cant change was observed in the score for aggres-
siveness in either group, indicating that this parameter was not 
affected by the treatment provided. These results obtained in 
hypogonadal men are paralleled in some respects by the study 
of O’Connor et al (2004) showing that a single injection of 
1000 mg TU to 28 eugonadal young men, elevating mean T 
levels above normal, was associated with signiﬁ  cant increases 
in anger-hostility from baseline to week 2 after the injection. 
It was accompanied by an overall reduction in fatigue-inertia, 
and did not increase aggressive behavior or induce any changes 
in non-aggressive or sexual behavior.
It is clear now that TU is at least as effective and safe as the 
standard injectable formulation and requires only 4 injections 
per year in long-term treatment while maintaining serum T lev-
els within the physiological range. There are data to conﬁ  rm the 
safety and efﬁ  cacy of long-term TU therapy of hypogonadal 
patients treated over a period of more than 8 years (Zitzmann 
2006). The study included 22 patients who received TU up 
to 8.5 years at injection intervals of approximately 12-weeks. 
Patients reported restoration of sexual functions and positive 
changes in mood patterns. In contrast to short-acting TE prepa-
rations, patients rarely reported perceptions of ﬂ  uctuations in 
androgen concentrations. Over the whole treatment period, 
prostate speciﬁ  c antigen (PSA) concentrations did not exceed 
the normal range and prostate size remained below 30 mL in 
all patients (Figure 3). Hemoglobin and hematocrit increased 
initially during treatment but remained within the normal 
range over the entire treatment period. Computer tomography 
of the lumbar spine showed that bone density improved in all 
patients during the ﬁ  rst 2 years and remained stable thereafter. 
Body mass index (BMI) decreased during the ﬁ  rst 2 years of 
treatment. Serum total cholesterol levels did not change over 
the treatment period and serum LDL levels decreased slightly, 
concurring with the decrease of BMI, and serum HDL levels 
increased slightly over time. There were no relevant changes 
in blood pressure or heart rate. Overall, treatment with in-
tramuscular TU appeared to have beneﬁ  cial effects on body 
composition and lipid proﬁ  le (Zitzmann et al 2005).
The above studies were conﬁ  rmed recently by a study in 
elderly men (Jacobeit and Schulte 2006).
Thirty-three hypogonadal men with primary, secondary, 
or late-onset hypogonadism between the ages of 45 and 79 
years were treated with TU. Serum T levels increased from 
9.0 ± 3.8 nmol/L at baseline to 13.5 ± 4.6 nmol/L after 
6-weeks and to 16.4 ± 6.4 nmol/L after 30-weeks of treat-
ment. DHT levels increased from 0.98 ± 0.48 nmol/L to 3.1 
± 1.0 nmol/L. Serum PSA levels ﬂ  uctuated minimally in the 
normal range. In 2 patients the length between two injections 
could be prolonged from 12 to 14-weeks. All patients re-
ported improved mood, sexual function and quality of life.
Testosterone gel versus long-acting 
injectable testosterone undecanoate
In a study of Yassin et al (2007), 2 modern modes of tes-
tosterone treatment were compared: transdermal T gel and 
injectable long-acting TU. Thirty-four men between the ages 
of 49 and 70 years (median 61) were hypogonadal by clinical 
and laboratory criteria (T <2.3 ng/mL). They received ﬁ  rst 
5 g daily of T gel for 9 months and subsequently TU for 9 
months. Large numbers of variables were monitored under 
both T regimens and analyzed with Student’s t-tests From 
the observations in androgen-deﬁ  cient men, treated with T 
gel followed by TU, it appeared that plasma T rose slowly 
over 9 months in patients receiving T gel, and that there was Clinical Interventions in Aging 2007:2(4) 584
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an additional rise of plasma T when patients are treated with 
TU, with T values remaining in the normal range. The waist 
circumference declined upon elevation of plasma T. Waist 
circumference is a key diagnostic marker of the metabolic 
syndrome. Further, there was an improvement of lipid proﬁ  les 
(associated with the decline in waist circumference). Hemo-
globin and hematocrit values rose in patients whose plasma T 
levels were normalized and there was an improvement of the 
scores of the AMS test. There was no effect on PSA values 
or international prostate symptom score, no effect on liver 
functions, and no effect on DHT:T ratio.
So far, the two types of testosterone treatment have not 
been compared for their beneﬁ  ts and potential drawbacks. 
While both types meet largely the speciﬁ  cations for require-
ments of present day androgen treatment, the higher levels 
achieved with TU compared to the T gel appeared to be 
efﬁ  cacious.
Treatment of erectile dysfunction (ED) 
with TU
There is a new interest in the treatment of erectile dysfunc-
tion with testosterone. Apart from its well-known effects on 
libido, testosterone appears to have signiﬁ  cant direct effects 
on anatomical and physiological properties of erectile tissue 
(Gooren and Saad 2006; Traish and Guay 2006), and there 
are some interesting new observations. In support of a direct 
effect of testosterone on penile tissues, treatment with TU 
appeared to improve veno-occlusive dysfunction evidenced 
by cavernosographic changes in hypogonadal patients with 
severe ED, diabetes mellitus, obesity, and/or metabolic 
syndrome who had earlier not responded to PDE5 inhibitors 
and intracavernosal alprostadil injections (Yassin and Saad 
2006b). One patient having venous leakage to T administra-
tion received treatment with TU at 12- to 14-week intervals 
following a loading dose of 6-weeks. The patient showed 
improved sexual function after 9-weeks of treatment and 
repeated cavernosography after 12-weeks revealed that the 
venous leakage had receded (Yassin and Saad 2006a). The 
results from this case study suggest that TU has a positive 
impact on the veno-occlusive properties of penile trabecular 
tissues in hypogonadal ED patients (Figure 4). This ﬁ  nding 
has been replicated in 5 out of 12 hypogonadal patients 
(Yassin et al 2006) and could suggest the correction of venous 
leak, which could be at least, in part, a metabolic lesion, rather 
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Figure 2 Sexual parameters in 40 hypogonadal men (mean age 41, range: 18–74 years) under treatment with testosterone enanthate or testosterone undecanoate.Clinical Interventions in Aging 2007:2(4) 585
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than a mechanical one, such as in venous anatomic abnormality 
or venous valves dysfunction, and could also perhaps clarify 
the higher recurrence rate in penile venous surgery (Figure 5). 
These results conﬁ  rm data obtained from animal studies 
showing that androgen insufﬁ  ciency leads to veno-occlusive 
dysfunction which cannot be restored with PDE-5 inhibitor 
treatment alone (Traish et al 2005).
In a study assessing the impact of T therapy alone on ED, 
22 hypogonadal men with ED received injections with TU, 
and sexual function was assessed using the International Index 
of Erectile Function (IIEF). While in all patients T therapy 
alone signiﬁ  cantly improved the sexual desire domain of 
the IIEF (from 4.5 to 8.4 on a scale of 10), in 12 out of 22 
patients (54%), the erectile function domain score increased 
from 12 at baseline (moderate ED) to 25 (indicating normal 
erectile function) at week 24. It is of note that the effect of T 
on erectile function may appear as late as after 12–24-weeks 
of administration of T (Yassin and Saad 2006b).
These observations have been extended to larger groups 
of patients, conﬁ  rming the results of the above study (Yassin 
et al 2006) (Figure5). Data obtained from this cohort are real-
istic. Since the subjects are testosterone deﬁ  cient, they have 
primarily organic reasons for ED, but of course, psychogenic 
components might play a role in increasing average of erectile 
function to this level.
Safety and tolerability
TU is generally well tolerated. Local irritation at the site of 
injection is moderate, does not last longer than 3 days and can 
be minimized by administering TU slowly over a period of at 
least 1 minute. Very few patients reported irritation or pain 
at the sight of injection despite the large volume of injection 
of 4 mL. No patient discontinued treatment due to problems 
of local discomfort. TU should be injected deeply into the 
gluteal muscle. The patient should be in a prone position. 
During the ﬁ  rst year of TU treatment, for safety reasons, 
erythropoiesis parameters and prostate size and serum PSA as 
well as international prostate symptoms score (IPSS) should 
be monitored in men above the age of 45 years at quarterly 
intervals and then yearly thereafter (Nieschlag et al 2005).
The conventional injectable T esters, such as TE with injec-
tion intervals of 2–3-weeks, are associated with supraphysiologi-
cal peak values shortly after the injection and to subphysiological 
levels in the days before the new injection. This often leads 
to mood swings or emotional instability. Another important 
consequence of the supraphysiological T levels under treatment 
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Figure 4 Disappearance of venous leakage evidenced by cavernosography in a hypogonadal man with erectile dysfunction at baseline (left) and after 3 months’ administra-
tion of testosterone undecanoate (right). 
Figure 5 Another subject showing absence of venous leakage evidenced by cavernosography in a hypogonadal man with erectile dysfunction at baseline (left) and after 4.5 
months’ administration of testosterone undecanoate (right) with better penile composition and opaciﬁ  cation. Clinical Interventions in Aging 2007:2(4) 587
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with TE is the induction of elevations of the hematocrit. Of 70 
older men with low serum T receiving 200 mg of TE every other 
week, 30% developed a hematocrit greater than 52% (Dobs et 
al 1999; Gui et al 2004). In another study, of 32 hypogonadal 
men receiving 200 mg TE every other week, 14 patients (43.8%) 
had at least one occurrence of an elevated hematocrit value 
(Jockenhovel et al 1997). The evidence that elevated hema-
tocrit values may lead to thrombo-embolic events is not very 
well documented. It is clear now that TU is at least as effective 
and safe as the standard injectable formulation and eventually 
requires only 4 injections per year while maintaining serum T 
levels within the physiological range. There are data to conﬁ  rm 
the safety and efﬁ  cacy of long-term TU therapy in hypogonadal 
patients treated over a period of more than 8 years.
No major adverse effects were encountered in the clinical 
trials of TU. This is not surprising since the pharmaceuti-
cally active component is T itself. Common side effects of 
T administration, such as gynecomastia, breast tenderness, 
and acne were, reported in only a minority of patients. This 
absence of side effects is probably to be ascribed to the largely 
normal physiological levels of T, and its derivatives DHT and 
estradiol, achieved with TU. Adverse effects were observed 
in the initial studies when the dosing schedule was not yet 
well established and the higher frequency of administration of 
TU led to higher-than-normal levels of testosterone. Signiﬁ  -
cant increase in PSA and prostate size were noted in some of 
these trials; however, this is due to the fact that hypogonadal 
men have subnormal PSA values and small prostate sizes at 
baseline and is observed with every treatment modality of T 
administration upon normalization of plasma T levels (Behre 
et al 1994; Bhasin et al 2006). In a systematic review of the 
effect of T administration on the prostate in hypogonadal 
men, the average PSA increase after initiation of testosterone 
therapy was 0.3 ng/mL in young, hypogonadal men and 0.44 
ng/mL in older men (Bhasin et al 2003).
In the further course of treatment with TU, PSA levels and 
prostate size remained stable and within the normal range. 
Similarly, increases of parameters of erythropoiesis to eugo-
nadal values were observed, but there was no occurrence of 
polycythemia as observed in studies with the more traditional T 
esters (Jockenhovel et al 1997; Dobs et al 1999). Only one study 
showed a transient decline in serum HDL cholesterol; however, 
its value remained within the normal range (for a review see Harle 
et al 2005). So, TU appears to be a safe modality of T treatment, 
because of the fact that with the presently established dosage 
regimen, plasma T levels remain in the physiological range.
Several of the recommendations of testosterone admin-
istration to elderly men with late onset hypogonadism argue 
in favor of short-acting testosterone preparations (Nieschlag 
et al 2005). The reasoning is that in case an concurrent disease 
develops, such as prostate malignancy, the impact of the extra 
androgens provided by the administration of testosterone will 
be short-lived. It is questionable whether this recommenda-
tion is rational 1) In view of the fact that there is an early 
diagnosis in this group of men who supposedly are monitored, 
following the guidelines, with an absolute minimum of digital 
rectal examination plus PSA determination once a year; 2) 
In view of the fact that delays between diagnostic biopsies 
and treatment of several months up to one year did not affect 
the recurrence rate as measured by PSA levels. The modern 
testosterone preparations generate physiological testosterone 
levels for a maximum duration of 10–14-weeks. So, it would 
seem that the choice of longer-acting testosterone preparation 
is not of great pathophysiological relevance (Boorjian et al 
2005; Graefen et al 2005; Morgentaler and Rhoden 2006); 3) 
With the modern testosterone preparations, plasma testoster-
one remain in the normal range, so there is no over-exposure 
of the prostate to testosterone; 4) Even with the traditional 
testosterone esters, with supraphysiological levels shortly 
after administration, no cause and effect of prostate cancer 
to treatment with testosterone has been found. 5) Men diag-
nosed with prostate cancer do not routinely undergo androgen 
ablation treatment. So it would seem that there is no serious 
objection against treating elderly men with a long-acting 
testosterone preparation.
Patient-focused perspectives such 
as quality of life, patient satisfaction/
acceptability, adherence, and uptake
Most medical conditions requiring androgen therapy are 
irreversible. As a consequence, androgen replacement 
Figure 6 Improvement in scores on the international index of erectile function 
(IIEF) in 71 of 122 patients receiving treatment with long-acting testosterone 
undecanoate. 
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therapy often extends over many decades. Therefore, patient 
compliance is of utmost importance.
After a recommended loading dose of two injections 
at a 6-week interval, TU is the ﬁ  rst intramuscular agent 
that can be administered every 12-weeks thus maintaining 
physiological plasma T levels. Depending on the trough 
plasma T level immediately before the next injection and 
clinical symptoms of the patient, adjustment of the injection 
interval is desirable, rarely by shortening (every 10–11-
weeks) or more often by prolonging (every 13–14-weeks) 
the interval between two injections. TU produces fewer 
peaks and troughs in serum T levels in comparison with 
the traditional T esters. Hypogonadal men treated with TU 
report a general sense of well-being and normal sexual func-
tion during treatment. These parameters were not different 
when evaluated at the half point of injection intervals versus 
the end of the injection interval period. This suggests that 
normal physiological T values were maintained throughout 
the 12-week period, without major ﬂ  uctuations. As a result, 
patients did not report mood-swings or emotional instability, 
which is a common complaint with other T preparations.
A major advantage of TU is that it only requires 4 injec-
tions/year compared with 26 injections/year of TE (although 
if taken at a dose of 200 or 250 mg every 2-weeks, which 
is necessary if the plasma T levels are to be kept in the 
physiological range, with this frequency, plasma T levels will 
exceed to the supraphysiological range in the days following 
an injection). The physician sees the patient every 12-weeks 
for safety and efﬁ  cacy monitoring. With a 2- to 3-weekly injec-
tion of TE, the frequency is so high that not every visit will be 
regarded as a moment of reﬂ  ection on efﬁ  cacy and safety of 
T administration. The clinical experience with TU meets the 
requirements spelt out in the consensus on T as well as other 
recommendations regarding safety and efﬁ  cacy monitoring 
of T administration. Therefore, TU is also well suited for 
elderly men because these patients will be examined 4 times 
per year and a prostate malignancy and other reasons for the 
discontinuation of the therapy can be diagnosed in a timely 
manner. There was no impairment of urine ﬂ  ow.
Conclusions, place in therapy
Treatment with the unmodiﬁ  ed T molecule is preferred by 
opinion leaders, with a treatment modality and in a dose 
which maintains serum T in the physiological range for 
the full 24 hours of the day. Studies so far show that TU 
represents an effective, safe, and well tolerated means of 
androgen treatment in hypogonadal men. At present, clini-
cal experience is available with TU treatment over 9 years 
(Zitzmann et al 2007). In view of its favorable pharmacoki-
netic proﬁ  le TU has been well received. Its advantages over 
the more conventional injectable T preparations are obvious. 
The injection frequency is as little as 4 per year. The large 
ﬂ  uctuations of plasma testosterone with the conventional 
T esters are subjectively experienced as unpleasant by 
many patients. TU, with its more favorable pharmocokinetic 
proﬁ  le, did not have these side effects in clinical trials. So 
the merits of TU are manifest. The traditional testosterone 
esters developed some 50–60 years ago are relatively cheap. 
Health economics may delay a wide introduction of TU in 
the short-term in spite of the obvious advantages over the 
traditional T esters.
TU treatment is indicated for all forms of hypogonad-
ism. Men with ED and low T may also beneﬁ  t from TU 
administration, and the combination of phosphodiesterease 5-
inhibitors and TU may be indicated in men who do not respond 
sufﬁ  ciently to phosphodiesterease 5-inhibitors alone.
The open questions are related to T therapy in general and 
apply to other T preparations as well, and relate to prostate 
cancer. There is no evidence that testosterone causes prostate 
cancer. But larger, longer-term clinical studies with more 
patients (comprising 6000 men followed up for 6–8 years) are 
required to ﬁ  nd deﬁ  nitive answers on the interrelationships 
between T serum levels and the pathophysiology of prostate 
cancer. However, experts agree that it is responsible clinical 
practice to treat elderly hypogonadal men with T provided 
the existing guidelines for monitoring are followed.
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